Stockscreener 앱 받기
12.92
2.78%
0.35
시간 외 거래:
13.00
0.08
+0.62%
전일 마감가:
$12.57
열려 있는:
$12.57
하루 거래량:
8.59M
Relative Volume:
1.47
시가총액:
$8.82B
수익:
$125.68M
순이익/손실:
$4.81B
주가수익비율:
2.2867
EPS:
5.65
순현금흐름:
$-781.21M
1주 성능:
+8.30%
1개월 성능:
+11.09%
6개월 성능:
+20.75%
1년 성능:
+5.99%
1일 변동 폭
$12.54
$13.04
1주일 범위
$11.94
$13.08
52주 변동 폭
$8.73
$13.08
Roivant Sciences Ltd Stock (ROIV) Company Profile
명칭
Roivant Sciences Ltd
전화
441-295-5950
주소
7TH FLOOR, 50 BROADWAY, LONDON
ROIV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
12.92 | 8.58B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-02 | 개시 | Citigroup | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-01-05 | 개시 | Piper Sandler | Overweight |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-17 | 개시 | Guggenheim | Buy |
| 2023-06-08 | 개시 | BofA Securities | Neutral |
| 2022-10-27 | 개시 | JP Morgan | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-15 | 개시 | Goldman | Buy |
| 2021-11-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-28 | 개시 | Citigroup | Buy |
| 2021-10-26 | 개시 | Cowen | Outperform |
| 2021-10-26 | 개시 | Jefferies | Buy |
| 2021-10-26 | 개시 | Truist | Buy |
모두보기
Roivant Sciences Ltd 주식(ROIV)의 최신 뉴스
Should I hold or sell Roivant Sciences Ltd. nowProfit Target & Capital Protection Trading Alerts - خودرو بانک
What is the cash position of Roivant Sciences Ltd.Market Sentiment Report & Real-Time Stock Price Movement Reports - خودرو بانک
Real time pattern detection on Roivant Sciences Ltd. stockJuly 2025 Opening Moves & Detailed Earnings Play Strategies - Newser
Is Roivant Sciences Ltd. stock undervalued right nowTrade Performance Summary & Growth Focused Entry Reports - خودرو بانک
Roivant Sciences Ltd. stock trend outlook and recovery pathWeekly Profit Recap & Stepwise Trade Signal Guides - Newser
Candlestick signals on Roivant Sciences Ltd. stock todayQuarterly Earnings Report & Safe Entry Point Alerts - Newser
Order flow analysis tools used on Roivant Sciences Ltd.July 2025 Macro Moves & Free Technical Pattern Based Buy Signals - Newser
Can Roivant Sciences Ltd. outperform in the next rallyJuly 2025 Weekly Recap & Weekly High Momentum Picks - خودرو بانک
What machine learning models say about Roivant Sciences Ltd.Portfolio Return Report & Long-Term Growth Plans - Newser
Tools to monitor Roivant Sciences Ltd. recovery probabilityWeekly Trend Report & Entry and Exit Point Strategies - Newser
Is Roivant Sciences Ltd. stock a good hedge against inflationJuly 2025 Retail & Risk Adjusted Buy/Sell Alerts - Newser
Is Roivant Sciences Ltd. stock bottoming outEarnings Recap Report & Weekly High Conviction Ideas - Newser
Combining price and volume data for Roivant Sciences Ltd.2025 Key Highlights & Consistent Return Investment Signals - Newser
Will Roivant Sciences Ltd. outperform the marketMarket Weekly Review & Safe Capital Growth Trade Ideas - Newser
Roivant Sciences stock hits 52-week high at 13.06 USD - Investing.com
How institutional ownership impacts Roivant Sciences Ltd. stockWeekly Risk Summary & Fast Exit/Entry Strategy Plans - Newser
Can swing trading help recover from Roivant Sciences Ltd. lossesIndex Update & Risk Controlled Swing Trade Alerts - Newser
Roivant Sciences' Mosliciguat Granted Orphan Drug Designation in Japan - MarketScreener
Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) - GlobeNewswire Inc.
Signal Recap: How volatile is Roivant Sciences Ltd. stockJuly 2025 Pullbacks & Low Risk Investment Opportunities - خودرو بانک
Automated trading signals detected on Roivant Sciences Ltd.Quarterly Profit Report & Daily Entry Point Trade Alerts - Newser
How to build a custom watchlist for Roivant Sciences Ltd.Portfolio Performance Report & Long-Term Capital Growth Strategies - Newser
Should you hold or exit Roivant Sciences Ltd. nowIPO Watch & Long-Term Capital Growth Strategies - Newser
What candlestick patterns are forming on Roivant Sciences Ltd.July 2025 Fed Impact & Smart Investment Allocation Tips - Newser
Is Roivant Sciences Ltd. backed by strong institutional buying2025 Short Interest & Daily Entry Point Alerts - خودرو بانک
Transcript : Roivant Sciences Ltd.Special Call - MarketScreener
Forecasting Roivant Sciences Ltd. price range with options data2025 Breakouts & Breakdowns & Free Expert Verified Stock Movement Alerts - Newser
Will Roivant Sciences Ltd. see short term momentumMarket Sentiment Report & Real-Time Buy Signal Notifications - Newser
Using RSI to spot recovery in Roivant Sciences Ltd.July 2025 Pullbacks & Free Growth Oriented Trading Recommendations - Newser
Short interest data insights for Roivant Sciences Ltd.July 2025 Gainers & Free Real-Time Volume Trigger Notifications - Newser
Can Roivant Sciences Ltd. ride the EV waveQuarterly Trade Review & Weekly Stock Performance Updates - خودرو بانک
Technical analysis overview for Roivant Sciences Ltd. stock2025 Bull vs Bear & Growth Focused Entry Point Reports - Newser
Is Roivant Sciences Ltd. forming a reversal patternEarnings Summary Report & AI Driven Stock Movement Reports - Newser
Will a bounce in Roivant Sciences Ltd. offer an exitJuly 2025 PreEarnings & Weekly High Momentum Picks - Newser
Roivant Sciences Ltd. stock daily chart insightsJuly 2025 Big Picture & High Accuracy Trade Signal Alerts - Newser
Citi Initiates Roivant Sciences(ROIV.US) With Buy Rating, Announces Target Price $16 - 富途牛牛
Roivant Sciences stock rating reiterated by TD Cowen ahead of trial data - Investing.com UK
Citigroup initiates coverage on Roivant Sciences with Buy rating and $16 price target. - AInvest
How to monitor Roivant Sciences Ltd. with trend dashboardsWeekly Market Report & Capital Efficiency Focused Ideas - Newser
Will Roivant Sciences Ltd. bounce back from current supportEarnings Recap Summary & Daily Entry Point Alerts - Newser
Trading Bots Trigger Alerts on Roivant Sciences Ltd. Activity getLinesFromResByArray error: size == 0 - thegnnews.com
How to use Fibonacci retracement on Roivant Sciences Ltd.Portfolio Return Report & Safe Entry Zone Identification - Newser
Analyzing Roivant Sciences Ltd. with risk reward ratio chartsJuly 2025 Price Swings & Expert Curated Trade Setup Alerts - Newser
Chart overlay techniques for tracking Roivant Sciences Ltd.Stop Loss & Verified Stock Trade Ideas - Newser
Building trade automation scripts for Roivant Sciences Ltd.Global Markets & Proven Capital Preservation Tips - Newser
Identifying reversal signals in Roivant Sciences Ltd.July 2025 Fed Impact & AI Driven Price Forecasts - Newser
Roivant Sciences Ltd (ROIV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.40%
자본화:
|
볼륨(24시간):